1                                              99mTc-MAG3 renal scans were grossly abnormal in the allo

2 i (minimum 2 mCi) of the dynamic renal agent 99mTc-MAG3.

3 enal function was evaluated first by dynamic 99mTc-MAG3 imaging, and subsequently, 99mTc-labeled FGF-

4 rrection and probably should not be used for 99mTc-MAG3.

5 high tumor-to-blood and -tissue ratios makes 99mTc-MAG3-dsFv a promising agent for scintigraphic dete

6 r intravenous injections of 10 mCi (370 MBq) 99mTc-MAG3 and 40 mg furosemide (at zero time, or F0).

7 e imaged supine after 111-370 MBq (3-10 mCi) 99mTc-MAG3 injection.

8 ction, single-sample procedure for measuring 99mTc-MAG3 clearance is presented that incorporates scal

9 stfurosemide 99mTc-mercaptoacetyltriglycine (99mTc-MAG3) scans.

10  to those of 99mTc-mercaptoacetyltriglycine (99mTc-MAG3); however, to better define the potential of

11  formula to predict the urinary excretion of 99mTc-MAG3 has been developed and prospectively validate

12 thod for predicting the urinary excretion of 99mTc-MAG3 is presented.

13 labeled with 99mTc, and the carboxy group of 99mTc-MAG3 was then activated to the corresponding tetra

14                      The immunoreactivity of 99mTc-MAG3-dsFv was 76% +/- 9%.

15                          The tumor uptake of 99mTc-MAG3-dsFv was rapid with tumor-to-blood or tumor-t

16                          The tumor uptake of 99mTc-MAG3-dsFv was similar to that of 125I-dsFv.

17 al obstruction using pre- and postfurosemide 99mTc-MAG3 renal scans, at a standardized expert level.

18                                The resulting 99mTc-MAG3-dsFv was purified with PD-10 size-exclusion c

19 7 quantitative parameters extracted from the 99mTc-MAG3 scans of 100 potential renal donors.